About the Company
neurobo pharmaceuticals, inc., a clinical-stage biotechnology company provides therapies for neurodegenerative and cardiometabolic diseases. its therapeutics programs include nb-01 for the treatment of painful diabetic neuropathy; nb-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein; and gemcabene, which is focused on developing and commercializing therapies for the treatment of dyslipidemia. neurobo pharmaceuticals, inc. was incorporated in 2017 and is headquartered in boston, massachusetts.
Exchange
NASDAQ
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $NRBO News
NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update
NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the year ended December 31, ...
Ad Campaign for Weight-Loss Drugs Reinforces Proper Use
Eli Lilly and Company, which manufactures one of the new weight-loss drugs, has launched an advertising campaign reinforcing ...
PRISM MarketView Spotlights Companies Leading the Charge in Liver Disease Treatment Following Landmark FDA Approval
PRISM MarketView takes a closer look at five of our top picks for delivering the next potential treatments for the liver ...
Tonix picks CMOs for potential launch of fibromyalgia drug
Tonix (TNXP) said it has selected two CMOs as suppliers for the potential US launch of its non-opioid pain reliever Tonmya ...
Biora Therapeutics, Inc. (NASDAQ:BIOR) Q4 2023 Earnings Call Transcript
March 26, 2024 Biora Therapeutics, Inc. isn't one of the 30 most popular stocks among hedge funds at the end of the third ...
Metagenomi, Inc.: Strong Buy Rating on Robust Hemophilia Program and Strategic Partnerships
In a report released yesterday, Yanan Zhu from Wells Fargo maintained a Buy rating on Metagenomi, Inc. (MGX – Research Report), with ... moves made by Metagenomi in partnership with Ionis ...
Biogen Inc. (BIIB) Dips More Than Broader Market: What You Should Know
Biogen Inc. (BIIB) closed at $216.69 in the latest trading session, marking a -0.65% move from the prior day. This change lagged the S&P 500's daily loss of 0.31%. Elsewhere, the Dow lost 0.41%, while ...
Biotech Stock News Bite - Heron Therapeutics, Inc. (Nasdaq: HRTX) Higher on Fourth Quarter and Full-Year 2023 Financial Results
March 13, 2024 (Investorideas.com Newswire) Investorideas.com ( www.investorideas.com) Biotech Stock News Bites - Heron ...
NeuroBo Pharmaceuticals, Inc.: NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update
March 28, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results ...
Loading the latest forecasts...